User login
Highlights in Relapsing-Remitting Multiple Sclerosis From AAN 2022
Dr Aaron Miller, from the Icahn School of Medicine at Mount Sinai in New York, discusses updates in relapsing-remitting multiple sclerosis (RRMS) presented at the 2022 American Academy of Neurology (AAN) Annual Meeting.
Dr Miller reports on compelling outcomes linking adherence to an MS-prescribed Mediterranean diet with increased thalamic volume and an enhanced predictability of functional composite scoring.
Next, Dr Miller turns to DMTs and discusses two abstracts looking at results of ublituximab in regard to expanded disability status scale (EDSS) scores and no evidence of disease activity (NEDA) status, and a third comparing ublituximab with teriflunomide.
Finally, Dr Miller presents promising data on Bruton tyrosine kinase inhibitors tolebrutinib and evobrutinib, and the latest results of the NOVA study on the monoclonal antibody natalizumab.
--
Professor, Department of Neurology; Medical Director, Corinne Goldsmith Dickinson Center for Multiple Sclerosis, Academic Medical Center, Icahn School of Medicine at Mount Sinai, New York, NY
Aaron Miller, MD, has disclosed no relevant financial relationships.
Dr Aaron Miller, from the Icahn School of Medicine at Mount Sinai in New York, discusses updates in relapsing-remitting multiple sclerosis (RRMS) presented at the 2022 American Academy of Neurology (AAN) Annual Meeting.
Dr Miller reports on compelling outcomes linking adherence to an MS-prescribed Mediterranean diet with increased thalamic volume and an enhanced predictability of functional composite scoring.
Next, Dr Miller turns to DMTs and discusses two abstracts looking at results of ublituximab in regard to expanded disability status scale (EDSS) scores and no evidence of disease activity (NEDA) status, and a third comparing ublituximab with teriflunomide.
Finally, Dr Miller presents promising data on Bruton tyrosine kinase inhibitors tolebrutinib and evobrutinib, and the latest results of the NOVA study on the monoclonal antibody natalizumab.
--
Professor, Department of Neurology; Medical Director, Corinne Goldsmith Dickinson Center for Multiple Sclerosis, Academic Medical Center, Icahn School of Medicine at Mount Sinai, New York, NY
Aaron Miller, MD, has disclosed no relevant financial relationships.
Dr Aaron Miller, from the Icahn School of Medicine at Mount Sinai in New York, discusses updates in relapsing-remitting multiple sclerosis (RRMS) presented at the 2022 American Academy of Neurology (AAN) Annual Meeting.
Dr Miller reports on compelling outcomes linking adherence to an MS-prescribed Mediterranean diet with increased thalamic volume and an enhanced predictability of functional composite scoring.
Next, Dr Miller turns to DMTs and discusses two abstracts looking at results of ublituximab in regard to expanded disability status scale (EDSS) scores and no evidence of disease activity (NEDA) status, and a third comparing ublituximab with teriflunomide.
Finally, Dr Miller presents promising data on Bruton tyrosine kinase inhibitors tolebrutinib and evobrutinib, and the latest results of the NOVA study on the monoclonal antibody natalizumab.
--
Professor, Department of Neurology; Medical Director, Corinne Goldsmith Dickinson Center for Multiple Sclerosis, Academic Medical Center, Icahn School of Medicine at Mount Sinai, New York, NY
Aaron Miller, MD, has disclosed no relevant financial relationships.
